ABSTRACT
Galectin-9 is a risk gene in inflammatory bowel disease. By transcriptomic analyses of ileal biopsies and PBMCs from inflammatory bowel disease patients, we identified a positive correlation between galectin-9 expression and colitis severity. We observed that galectin-9-deficient T cells were less able to induce T cell-mediated colitis. However, several mouse-based studies reported that galectin-9 treatment induces T cell apoptosis and ameliorates autoimmune diseases in an exogenously modulated manner, indicating a complicated regulation of galectin-9 in T cells. We found that galectin-9 is expressed mainly inside T cells, and its secreted form is barely detected under physiological conditions. Endogenous galectin-9 was recruited to immune synapses upon T cell activation. Moreover, proximal TCR signaling was impaired in galectin-9-deficient T cells, and proliferation of these cells was decreased through an intracellularly modulated manner. Th17 cell differentiation was downregulated in galectin-9-deficient T cells, and this impairment can be rescued by strong TCR signaling. Taken together, these findings suggest that intracellular galectin-9 is a positive regulator of T cell activation and modulates the pathogenesis of autoimmune diseases.
Subject(s)
Autoimmune Diseases/immunology , Cell Differentiation/immunology , Galectins/immunology , Receptors, Antigen, T-Cell/immunology , Signal Transduction/immunology , Th17 Cells/immunology , Animals , Autoimmune Diseases/genetics , Autoimmune Diseases/pathology , Cell Differentiation/genetics , Galectins/genetics , Mice , Mice, Knockout , Receptors, Antigen, T-Cell/genetics , Signal Transduction/genetics , Th17 Cells/pathologyABSTRACT
B lymphocyte-induced maturation protein-1 (Blimp-1) serves as a master regulator of the development and function of antibody-producing B cells. Given that its function in T lymphocytes has been identified within the past decade, we review recent findings with emphasis on its role in coordinated control of gene expression during the development, differentiation, and function of T cells. Expression of Blimp-1 is mainly confined to activated T cells and is essential for the production of interleukin (IL)-10 by a subset of forkhead box (Fox)p3+ regulatory T cells with an effector phenotype. Blimp-1 is also required to induce cell elimination in the thymus and critically modulates peripheral T cell activation and proliferation. In addition, Blimp-1 promotes T helper (Th) 2 lineage commitment and limits Th1, Th17 and follicular helper T cell differentiation. Furthermore, Blimp-1 coordinates with other transcription factors to regulate expression of IL-2, IL-21 and IL-10 in effector T lymphocytes. In CD8+ T cells, Blimp-1 expression is distinct in heterogeneous populations at the stages of clonal expansion, differentiation, contraction and memory formation when they encounter antigens. Moreover, Blimp-1 plays a fundamental role in coordinating cytokine receptor signaling networks and transcriptional programs to regulate diverse aspects of the formation and function of effector and memory CD8+ T cells and their exhaustion. Blimp-1 also functions as a gatekeeper of T cell activation and suppression to prevent or dampen autoimmune disease, antiviral responses and antitumor immunity. In this review, we discuss the emerging roles of Blimp-1 in the complex regulation of gene networks that regulate the destiny and effector function of T cells and provide a Blimp-1-dominated transcriptional framework for T lymphocyte homeostasis.
Subject(s)
Lymphocyte Activation/genetics , Positive Regulatory Domain I-Binding Factor 1/genetics , Positive Regulatory Domain I-Binding Factor 1/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/metabolismABSTRACT
OBJECTIVE: The soluble preligand assembly domain (PLAD) of tumour necrosis factor receptor 1 (TNFR1) interferes with receptor trimerisation to block downstream signalling, and mediates Th17 suppression. We explored the therapeutic potential of recombinant PLAD.Fc protein on a spontaneous experimental colitis. DESIGN: A T-cell-specific BLIMP-1 knockout mouse model with mixed Th1/Th17 responses, resembling human Crohn's disease (CD) was established, and its colitogenic phenotype was characterised. Mice, 9 weeks old, were treated with PLAD.Fc protein at 5â mg/kg of body weight twice per week for 16â weeks, and presence of colitis was monitored by the appearance of diarrhoea, weight loss, and by histological colonic scoring. Activation status, cytokine profiles, and transcription factors in T cells were further analysed. RESULTS: The colitogenic phenotype in BLIMP-1 knockout mice was alleviated when an interleukin (IL)-23 knockdown transgene was introduced, indicating a therapeutic potential by downregulating IL-23-Th17 axis in these knockout mice. In PLAD.Fc-treated group, the mouse body weight remained stable and only mild disease scores were revealed. The percentage of naive CD4 T cells was increased and that of effector/memory CD4 T cells was decreased after PLAD.Fc-treatment. Moreover, the levels of IFN-γ, IL-17, IL-21, IL-22, IL-23R, granulocyte-macrophage colony-stimulating factor (GM-CSF) and TNF-α were diminished. Strikingly, Th2-associated cytokines (IL-4, IL-13 and IL-10) in sera, as well as percentages of Th2 cells, were increased in PLAD.Fc-treated mice. However, PLAD.Fc-mediated suppression of effector phenotypes in Th1/Th17 was abrogated after neutralising IL-10. CONCLUSIONS: The Th2 cytokine milieu induced by PLAD.Fc rebalanced T-helper cell subsets and conferred a protection against colitis in BLIMP-1 knockout mice.
Subject(s)
Crohn Disease/prevention & control , Molecular Targeted Therapy/methods , Recombinant Fusion Proteins/therapeutic use , Th17 Cells/immunology , Th2 Cells/immunology , Animals , CD4-Positive T-Lymphocytes/immunology , Crohn Disease/immunology , Disease Models, Animal , Disease Progression , Down-Regulation/immunology , Drug Evaluation, Preclinical/methods , Gene Deletion , Interleukin-23/immunology , Mice, Knockout , Positive Regulatory Domain I-Binding Factor 1 , Transcription Factors/deficiency , Transcription Factors/geneticsABSTRACT
Ptpn22 encodes PEST domain-enriched tyrosine phosphatase (Pep), which negatively regulates TCR proximal signaling and is strongly associated with a variety of autoimmune diseases in humans. The net effect of Pep on the balance of immunity and tolerance is uncertain because of the simultaneous inhibition of TCR-mediated signaling of effector and regulatory T cells (T(regs)). In this study, we generated transgenic NOD mice that overexpressed Pep in T cells. The transgenic mice had a significantly lower incidence of spontaneous autoimmune diabetes, which was accompanied by fewer IFN-γ-producing T cells, and an increased ratio of CD4(+)Foxp3(+) T(regs)to CD4(+)IFN-γ(+) or to CD8(+)IFN-γ(+) T cells, respectively, in pancreatic islets. Transgenic T cells showed markedly decreased TCR-mediated effector cell responses such as proliferation and Th1 differentiation. By contrast, the inhibitory effect of transgenic Pep on TCR signaling did not affect the differentiation of T(regs) or their suppressive activity. Adoptive transfer experiments showed that transgenic splenocytes exhibited attenuated diabetogenic ability. To examine further the pathogenic features of transgenic T cells, we generated Ptpn22/BDC2.5 doubly transgenic mice and found reduced proliferation and Th1 differentiation in CD4(+) T lymphocytes with additional Pep in pancreatic lymph nodes but not in inguinal lymph nodes of NOD/SCID recipients. This finding indicates that transgenic Pep attenuates T cell functions in an islet Ag-driven manner. Taken together, our results demonstrate that Pep overexpression in T cells attenuates autoimmune diabetes in NOD mice by preferentially modulating TCR signaling-mediated functions in diabetogenic T cells but not in T(regs).
Subject(s)
Diabetes Mellitus, Type 1/immunology , Protein Tyrosine Phosphatase, Non-Receptor Type 22/metabolism , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes, Regulatory/immunology , Animals , CD4 Antigens/biosynthesis , CD8 Antigens/biosynthesis , Cell Differentiation , Cell Proliferation , Cells, Cultured , Diabetes Mellitus, Type 1/epidemiology , Female , Forkhead Transcription Factors/biosynthesis , Genotype , Incidence , Interferon-gamma/biosynthesis , Male , Mice , Mice, Inbred NOD , Mice, Transgenic , Protein Tyrosine Phosphatase, Non-Receptor Type 22/genetics , Signal Transduction , T-Lymphocytes, Regulatory/metabolismABSTRACT
Drug resistance is an obstacle to the treatment of ovarian cancer. Using a unique cell model, we have proven previously that a subpopulation of ovarian cancer cells is more resistant to cisplatin than are the original cells. MicroRNAs (miRNAs), small noncoding RNAs, are involved in many biological events in cancer cells. In our study, we explored whether miRNAs are involved in cisplatin resistance of ovarian cancer cells. Cisplatin-resistant cells expressed a lower level of miR-29a/b/c. Manipulation of microRNA-29 (miR-29) expression modulated cisplatin sensitivity of CP70, HeyC2, SKOV3 and A2780 ovarian cancer cells. Knockdown of miR-29a/b/c increased the ability of cells to escape cisplatin-induced cell death partly through upregulation of collagen type I alpha 1 (COL1A1) and increased the activation of extracellular signal-regulated kinase 1/2 and inactivation of glycogen synthase kinase 3 beta. When combined with cisplatin treatment, knockdown of miR-29 decreased the amount of the active form of caspase-9 and caspase-3. Ectopic expression of miR-29 alone or in combination with cisplatin treatment efficaciously reduced the tumorigenicity of CP70 cells in vivo. Our data show that downregulation of miR-29 increases cisplatin resistance in ovarian cancer cells. Taken together, these data suggest that overexpression of miR-29 is a potential sensitizer to cisplatin treatment that may have therapeutic implications.
Subject(s)
Antineoplastic Agents/therapeutic use , Cisplatin/therapeutic use , Down-Regulation , MicroRNAs/physiology , Ovarian Neoplasms/genetics , Cell Line, Tumor , Collagen Type I/physiology , Collagen Type I, alpha 1 Chain , Drug Resistance, Neoplasm , Female , Humans , MicroRNAs/genetics , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathologyABSTRACT
Recently, we demonstrated that B lymphocyte-induced maturation protein 1 (BLIMP-1) has a role in regulating the differentiation and effector function of Th1 and Th17 cells. As these cells play critical roles in the induction and pathogenesis of experimental autoimmune encephalomyelitis (EAE), we investigated the potential role of T cell BLIMP-1 in modulating MOG35-55-induced EAE. We established T cell-specific BLIMP-1 conditional knockout (CKO) NOD mice to dissect the role of BLIMP-1 in EAE using loss-of-function model. Our results indicate that EAE severity is dramatically exacerbated in CKO mice. The numbers of CNS-infiltrating Th1, Th17, IFN-γ(+)IL-17A(+), and IL-21(+)IL-17A(+) CD4(+) T cells are remarkably increased in brain and spinal cord of CKO mice. Moreover, the ratio of Tregs/effectors and IL-10 production of Tregs are significantly downregulated in CNS of CKO mice. We conclude that BLIMP-1 suppresses autoimmune encephalomyelitis via downregulating Th1 and Th17 cells and impairing Treg cells.
Subject(s)
Encephalomyelitis, Autoimmune, Experimental/immunology , Gene Expression Regulation/immunology , Th1 Cells/physiology , Th17 Cells/physiology , Transcription Factors/metabolism , Adoptive Transfer , Animals , Brain/metabolism , Brain/pathology , CD4-Positive T-Lymphocytes , Cells, Cultured , Encephalomyelitis, Autoimmune, Experimental/genetics , Encephalomyelitis, Autoimmune, Experimental/metabolism , Mice , Mice, Inbred NOD , Mice, Knockout , Positive Regulatory Domain I-Binding Factor 1 , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , STAT4 Transcription Factor/genetics , STAT4 Transcription Factor/metabolism , Specific Pathogen-Free Organisms , Spinal Cord/metabolism , Spinal Cord/pathology , Transcription Factors/geneticsABSTRACT
Maf proteins are involved in a variety of biological processes, such as oncogenesis, lens development, and differentiation. In immune system, c-Maf transactivates IL-4 promoter, and ectopic expression of c-Maf skews primary T cell response toward the Th2 pathway. Numerous transcription factors are subjected to posttranslational modification. In this study, to our knowledge, we show for the first time that c-Maf is subjective to tyrosine phosphorylation in Th cells and that the level of its tyrosine phosphorylation positively correlates with IL-4 expression by peripheral Th cells, but is negatively associated with the severity of disease in NOD mice. c-Maf undergoes tyrosine phosphorylation at Tyr(21), Tyr(92), and Tyr(131) residues in Th2 cells. Furthermore, tyrosine phosphorylation at these three residues is critical for the recruitment of c-Maf to IL-4 promoter and IL-4 production in Th cells. Taken together, this study sheds new light on the role of posttranslational modification of c-Maf in IL-4 production and Th cell-mediated autoimmune diseases.
Subject(s)
Diabetes Mellitus, Type 1/metabolism , Gene Expression Regulation/physiology , Interleukin-4/biosynthesis , Proto-Oncogene Proteins c-maf/metabolism , Th2 Cells/metabolism , Animals , Blotting, Western , Diabetes Mellitus, Type 1/genetics , Female , HEK293 Cells , Humans , Immunoprecipitation , Interleukin-4/genetics , Mice , Mice, Inbred NOD , Microscopy, Confocal , Phosphorylation , Protein Processing, Post-Translational , Real-Time Polymerase Chain Reaction , Transfection , Tyrosine/metabolismABSTRACT
Measuring soft tissue thickness is an important step in rheumatoid disease research. The severity of mouse footpad swelling can be used as an indicator of disease progression. A noncontact footpad thickness assay, simplified geometry measurement system (SGMS), was developed that was able to reduce both intra- and interobserver variances during measurements. Three materials with five objects each were used in this study: hard blocks, soft sponges and mouse footpads. Thicknesses were measured using calipers or the SGMS. In the measurement of the hard block, there was no difference in measurement errors between calipers and SGMS. For the mouse footpad thickness, there was significant difference in intraobserver variances among three observers and a significant difference of interobserver variances between calipers and SGMS. In conclusions, this noncontact assay is reliable and highly reproducible for the assessment of inflammatory reactions when results are expressed as a gradual increase in footpad thickness.
Subject(s)
Arthritis, Experimental/diagnosis , Arthritis, Rheumatoid/diagnosis , Biological Assay/methods , Edema/pathology , Foot/pathology , Inflammation/diagnosis , Animals , Arthritis, Experimental/complications , Arthritis, Rheumatoid/complications , Disease Progression , Hindlimb/pathology , Inflammation/etiology , Male , Mice , Mice, Inbred BALB C , Observer Variation , Organ Size , Reproducibility of ResultsABSTRACT
OBJECTIVE: We studied the relationship between the severity of inflammation and IL-1beta production and relative expression level of IL-1beta mRNA in irrigation fluid and synovial tissue obtained from the knee joint during the acute stage of a murine model of type II collagen antibody-induced arthritis (CAIA). This model is used to identify potential therapeutic markers for treating rheumatoid arthritis. METHODS: Irrigation fluid and synovium tissue were harvested from the knee joint of BALB/c mice in acute stage of CAIA induction. The IL-1beta protein level was measured by enzyme-linked immunosorbent assay, and the relative expression level of IL-1beta mRNA was analyzed by reverse transcription-polymerase chain reaction. Two investigators analyzed expression levels and histopathological changes. RESULTS: IL-1beta concentration was higher in irrigation fluid from the knee joint than in the serum in the acute stage of CAIA. The relative expression level of IL-1beta mRNA was elevated in synovial tissue. Histopathological changes in the knee joint and foot indicated similar severity. CONCLUSIONS: IL-1beta concentration in irrigation fluid and relative expression level of IL-1beta mRNA in the synovium have potential as therapeutic markers in studying and treating CAIA.
Subject(s)
Arthritis, Experimental/genetics , Arthritis, Experimental/immunology , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Animals , Arthritis, Experimental/pathology , Biomarkers/blood , Biomarkers/metabolism , DNA Primers/genetics , Gene Expression , Inflammation/genetics , Inflammation/immunology , Inflammation/pathology , Interleukin-1beta/blood , Joints/immunology , Joints/pathology , Male , Mice , Mice, Inbred BALB C , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Synovial Fluid/immunology , Synovial Membrane/immunologyABSTRACT
SUMOylation is involved in the development of several inflammatory diseases, but the physiological significance of SUMO-modulated c-Maf in autoimmune diabetes is not completely understood. Here, we report that an age-dependent attenuation of c-Maf SUMOylation in CD4+ T cells is positively correlated with the IL-21-mediated diabetogenesis in NOD mice. Using 2 strains of T cell-specific transgenic NOD mice overexpressing wild-type c-Maf (Tg-WTc) or SUMOylation site-mutated c-Maf (Tg-KRc), we demonstrated that Tg-KRc mice developed diabetes more rapidly than Tg-WTc mice in a CD4+ T cell-autonomous manner. Moreover, SUMO-defective c-Maf preferentially transactivated Il21 to promote the development of CD4+ T cells with an extrafollicular helper T cell phenotype and expand the numbers of granzyme B-producing effector/memory CD8+ T cells. Furthermore, SUMO-defective c-Maf selectively inhibited recruitment of Daxx/HDAC2 to the Il21 promoter and enhanced histone acetylation mediated by CREB-binding protein (CBP) and p300. Using pharmacological interference with CBP/p300, we illustrated that CBP30 treatment ameliorated c-Maf-mediated/IL-21-based diabetogenesis. Taken together, our results show that the SUMOylation status of c-Maf has a stronger regulatory effect on IL-21 than the level of c-Maf expression, through an epigenetic mechanism. These findings provide new insights into how SUMOylation modulates the pathogenesis of autoimmune diabetes in a T cell-restricted manner and on the basis of a single transcription factor.
Subject(s)
Diabetes Mellitus, Type 1/etiology , Interleukins/genetics , Proto-Oncogene Proteins c-maf/metabolism , Sumoylation , Amino Acid Substitution , Animals , Benzimidazoles/pharmacology , Binding Sites/genetics , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/metabolism , Epigenesis, Genetic , Interleukins/biosynthesis , Isoxazoles/pharmacology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Mice, Transgenic , Models, Biological , Mutant Proteins/chemistry , Mutant Proteins/genetics , Mutant Proteins/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins c-maf/chemistry , Proto-Oncogene Proteins c-maf/genetics , Transcriptional Activation , p300-CBP Transcription Factors/antagonists & inhibitorsABSTRACT
Autoimmune regulator (Aire) is one of the most crucial genes expressed in the thymus, where it orchestrates the promiscuous expression and presentation of tissue-specific antigens during thymocyte selection. The presence of Aire-expressing cells outside the thymus points toward its plausible extrathymic functions; however, the relative contribution of Aire-expressing cells of hematopoietic origin and their role in the modulation of autoimmune diseases are still obscure. Here, we report that non-obese diabetic mice with transgenic Aire expression under the control of the CD11c (integrin alpha X) promoter were significantly protected from autoimmune diabetes compared with their non-transgenic littermates. The protective effect of Aire transgene was mediated primarily by an increase in the "exhausted" populations of CD4+ and CD8+ T cells, both demonstrating poor expressions of interferon-γ and tumor necrosis factor-α. Both CD4+ and CD8+ effector T cells in transgenic mice displayed distinctive and differential expression of T-bet and Eomesodermin, respectively, in conjunction with high expression of programmed cell death protein-1 and other exhaustion-associated markers. Importantly, transgenic Aire expression did not result in any detectable changes in the population of Foxp3+ regulatory T (Treg) cells. Co-transfer experiments also demonstrated that Aire transgenic dendritic cells, as a "stand-alone" cell population, had the potential to suppress effector T cells in vivo without the support of Treg cells, but eventually failed to prevent the diabetogenesis in recipient mice. In conclusion, our study suggests that apart from its role in clonal deletion of autoreactive T cells or clonal diversion to Treg lineage, Aire can also contribute to tolerance by forcing effector T cells into a state of exhaustion with poor effector functions, thereby effectively containing autoimmune diseases.
ABSTRACT
INTRODUCTION: Lupus nephritis (LN) is a major complication of systemic lupus erythematosus. NLRP3 inflammasome activation, reactive oxygen species (ROS) and mononuclear leukocyte infiltration in the kidney have been shown to provoke the acceleration and deterioration of LN, such as accelerated and severe LN (ASLN). Development of a novel therapeutic remedy based on these molecular events to prevent the progression of the disease is clinically warranted. METHODS: Citral (3,7-dimethyl-2,6-octadienal), a major active compound in a Chinese herbal medicine Litsea cubeba, was used to test its renoprotective effects in a lipopolysaccharide (LPS)-induced mouse ASLN model by examining NLRP3 inflammasome activation, ROS and COX-2 production as well as Nrf2 activation. The analysis of mechanisms of action of Citral also involved its effects on IL-1ß secretion and signaling pathways of NLRP3 inflammasome in LPS-primed peritoneal macrophages or J774A macrophages. RESULTS: Attenuated proteinuria, renal function impairment, and renal histopathology, the latter including intrinsic cell proliferation, cellular crescents, neutrophil influx, fibrinoid necrosis in the glomerulus, and peri-glomerular infiltration of mononuclear leukocytes as well as glomerulonephritis activity score were observed in Citral-treated ASLN mice. In addition, Citral inhibited NLRP3 inflammasome activation and levels of ROS, NAD(P)H oxidase subunit p47(phox), or COX-2, and it enhanced the activation of nuclear factor E2-related factor 2 (Nrf2). In LPS-primed macrophages, Citral reduced ATP-induced IL-1ß secretion and caspase-1 activation, but did not affect LPS-induced NLRP3 protein expression. CONCLUSION: Our data show that Citral alleviates the mouse ASLN model by inhibition of the activation signal, but not the priming signal, of NLRP3 inflammasome and enhanced activation of Nrf2 antioxidant signaling.
Subject(s)
Carrier Proteins/metabolism , Disease Models, Animal , Lupus Nephritis/drug therapy , Lupus Nephritis/metabolism , Monoterpenes/therapeutic use , NF-E2-Related Factor 2/metabolism , Acyclic Monoterpenes , Animals , Carrier Proteins/antagonists & inhibitors , Cell Line , Cells, Cultured , Drugs, Chinese Herbal/pharmacology , Drugs, Chinese Herbal/therapeutic use , Female , Inflammasomes/antagonists & inhibitors , Inflammasomes/metabolism , Litsea , Mice , Mice, Inbred NZB , Monoterpenes/pharmacology , NLR Family, Pyrin Domain-Containing 3 Protein , Severity of Illness Index , Signal Transduction/drug effects , Signal Transduction/physiologyABSTRACT
The objective of this study was to investigate the effects of photoperiods longer than 14 h of light:10 h of dark (14L:10D) during the rearing period on the age at first egg laying (AFE) and the subsequent reproductive performance in geese. Sixty-six White Roman geese (18 male and 48 female) were divided into three groups and subjected to different lighting schemes, i.e. natural lighting (NAT; 23 degrees 51'N, 120 degrees 33'E), 14L and 18L. Birds in 14L and 18L groups were exposed to 14L:10D or 18L:6D, respectively, beginning at 19 weeks of age and followed by a photoperiod of 10L:14D from 40 weeks of age. The natural photoperiod, including both dawn and dusk was between 11.5L:12.5D and 14.5L:9.5D. The results showed that the AFE was postponed (P < 0.05). Average weight of the first three eggs laid and the fertility of these eggs were improved (P < 0.05) for the geese in 14L and 18L groups when compared to those raised under natural lighting conditions. Meanwhile, the duration of laying were shifted from spring to autumn, with the peak laying rate in September and November instead of March. It was concluded that geese exposed to the photoperiod longer than 14L:10D for 21 weeks during the rearing period would suppress their AFE. Thereafter, the onset of laying could be induced by being transferred to the photoperiod of 10L:14D. The manipulation of photoperiodic regimes used in this study might have a potential benefit for geese farmers through improved weight and fertility of eggs.